The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
CRA announces vice president promotions
CRA is proud to announce the promotions of four new vice presidents: Andrea Asoni in the Antitrust & Competition Practice; Rachel Berk in the Risk,...